1. Maintenance Therapy in Advanced Ovarian Cancer

3. Introduction

4. Case 1: Medical History and Presentation

5. Case Evolution

6. PET-CT at Second Progression

7. Case Evolution (cont)

8. BRCA Testing Guidelines: Who? When? How?

9. BRCA1 and BRCA2 Tumoral and Germline Status Testing in the First-Line Setting

10. The Need for Maintenance Therapy After Response to Platinum in Recurrent Disease

11. PFS in SOLO-2 and NOVA

12. PARPi Clinical Benefit and Patient Selection: Olaparib

13. PARPi Clinical Benefit and Patient Selection: Niraparib

14. PARPi Clinical Benefit and Patient Selection: Rucaparib - ARIEL-3

15. Platinum Combination Followed by PARPi vs Platinum Combination With Bevacizumab

16. Case 2: Medical History and Presentation - Mrs JB, Aged 59 Years

17. Case 2: Medical History and Presentation - Mrs JB, Aged 59 Years (cont)

18. Long-Term Remissions on Treatment Are Possible: Olaparib

19. Clinical Characteristics of Long Responders (> 2 y) vs Short Responders (< 6 mo+)

20. PARPi Resistance Mechanisms

21. Adverse Events and Dose Modifications: Olaparib

22. TWiST Quality of Life Assessment: SOLO-2

23. Toxicity Profiles of PARP Inhibitors

24. Recommendations for the Management of Toxicities in Patients on Long-Term Olaparib

25. Conclusions

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)